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The cDNAs of several snake venom zinc endopeptidases code for a putative propeptide, which includes the conserved cysteine-containing sequence 
PKMCGVT. It has been suggested that binding of the cysteine thiol function to the active-site zinc, resulting in inactivation of the catalytic domain, 
occurs in a mode similar to the ‘cysteine switch’ mechanism proposed for matrix metalloproteinases. In order to confirm this hypothesis, inhibition 
kinetics have been performed on the metalloproteinase adamalysin II of the venom of the snake Crotalus adumanteus using several cysteine peptides. 
Among these the synthetic hexapeptide PKMCGV-NH*, corresponding to the conserved sequence portion of the known propeptides, was found 
to be by far the strongest inhibitor of this proteinase with a K, of 3.4,uM. The inhibitory potencies of an equivalent peptide with the L-Cys replaced 
by a D-Cys or by an t_-Ser as well as of reduced glutathione, cysteine and two unrelated cysteine peptides were by one to two orders of magnitudes 
lower. These findings strongly support a cysteine switch-Iike mechanism even for activation of the snake venom metalloproteinases. 
Cysteine switch; Matrix metalloproteinase; Snake venom metalloproteina~; Adamalysin; Proteinase activation; Stability of cysteine peptide 
1. INTRODUCTION 
The venom of poisonous snakes contains several 
pharmacologically active enzymes, among them zinc en- 
dopeptidases. The low-molecular weight zinc pro- 
teinases exhibit a highly conserved catalytic domain [ 11, 
which apparently is derived from larger precursors via 
post-translational proteolytic processing. The high-mo- 
lecular weight snake venom metalloproteinases consist 
of an N-terminal putative prodomain, a catalytic domain 
including the active-site zinc, a disintegrin domain and a 
cysteine-rich domain [Z-7]. Almost all of these metal- 
loproteinases how proteolytic activity against matrix 
proteins. They are most likely stored as inactive zymo- 
gens in order to prevent autodigestion, and are then 
activated by suitable proteolytic processing. A con- 
served PKMCGVT sequence located between the pro- 
posed signal sequence and the catalytic domain has 
been identified in the cDNA of the snake venom pro- 
teinases Ht-e 121, Jararhagin [5], Trigramin [4] and Rho- 
dostamin 181, and an activation mechanism has been 
suggested [2] similar to the cysteine switch as proposed 
for matrix metalloproteinases [9]. The cysteine thiol 
function in the precursor sequence should bind to the 
active-site zinc in the inactive zymogen, thereby 
blocking it. 
In the present study we have analyzed this hypothet- 
ical mechanism for adamalysin II, formerly called pro- 
teinase II [lo], a metalloproteinase of the venom of the 
eastern diamond rattlesnake ~~0~~~~~ ~u~~eus, the 
only snake venom metalloproteinase for which the terti- 
ary structure is available [l]. Although the precursor 
sequence of this protein is not known, we assume a 
similar or even identical sequence around the Cys resi- 
due as that found in the four known propeptides of 
snake venom metalloproteinases, i.e. the conserved 
PKMCGV region. Correspondingly, the peptide 
PKMCGV-NH, as well as other cysteine peptides were 
synthesized and analyzed comparatively for their inhib- 
itory potency. 
2. MATERIALS AND METHODS 
2.1. Synthetic peptides 
*Corresponding author. Fax: (49) (89) 8578 3516. 
Abbreviations: tandard abbreviations for amino acids and peptide 
derivatives are used as recommended by the IUPAC-IUB commission 
on biochemical nomenclature. The amino acids are of L-configuration 
unless stated otherwise. HPLC, high-pressure liquid chromatography; 
FAB-MS, fast atom bombardment mass spectroscopy; Abz, t-amino- 
benzoyl. 
The peptides used in the present study, i.e. H-Pro-Lys-Met-Cys- 
Gly-Val-NH,, H-Pro-Lys-Met-Ser-Gly-Val-NH, and H-Lys-Pro-Arg- 
Cys-Gly-Val-NH,, were synthesized in high-pressure continuous-flow 
reactors according to the Fmoc/tBu strategy [I I] using the modified 
Rink-linker on Tentagel S RAM resin (Rapp, Tubingen). Fmoc-Gly, 
Fmoc-Ser(tBu), Fmoc-Leu and Fmoc-Lys(Boc) were coupled as NCA 
derivatives [12], and Fmoc-Pro-OH, Fmoc-Val-OH, Fmoc-Cys(StBu)- 
OH and Fmoc-Arg(Pmc)-OH via TBTUIHOBtlDIEA (1: 1:2). Inter- 
mediate Fmoc removal and final acidolytic cleavage steps were per- 
formed as described previously 1131. Upon tributylphosphine-medi- 
ated reductive cleavage of the the S-tert-butylthio group, the crude 
products were purified by preparative HPLC on Lichroprep Cl 8 (15- 
76 Published b<v Elsevier Science Publishers B. K 
Volume 335. number 1 FEBS LETTERS November 1993 
25 pm) by linear gradient elution with CH,CN/O.l% t~fluoroa~tic 
acid. The products were isolated as lyophiliied materials and their 
homogeneity was determined by analytical HPLC on Nucleosil3W5 
C8 (linear gradient elution with CH,CN/2% phosphoric acid), quanti- 
tative amino acid analysis of the acid hydrolysates (6 M HCI contain- 
ing 2.5% thioglycolic acid, llO”C, 24 h), FAB-MS, and quantitative 
determination of the cysteine thiol group according to Grassetti and 
Murray [14]. H-Pro-Lys-Met-b-Cys-Gly-Val-NH2 was obtained as 
byproduct in the synthesis of the L-diastereomer, since coupling of 
Fmoc-Cys(StBu)-OH via the TBTU method is known to provoke 
racemization in the range of 2&30% [13]. H-Lys-Thr-Phe-Thr-Ser- 
Cys-OH and AC-Trp-Cys-Gly-Pro-NH, were synthesized previously 
by classical methods in solution ~unpublished results). Cysteine was 
purchased from Fluka, AC (Buchs, Swi~erland) and reduced gluta- 
thione from Sigma Chemie GmbH (~i~nhofen, Germany). 
Assay solutions of the peptides were prepared in the enzyme assay 
borate butl’er (pH 8.0). Peptide concentrations were determined by 
weight and peptide content as derived from quantitative amino acid 
analysis or thiol content. The stability of the cysteine peptides in the 
assay buffer has been analyzed on two representative compounds, i.e. 
reduced glutathione and KPRCGV-NH,, as follows: a 2 mM glutathi- 
one and a 0.8 mM KPRCGV-NH, solution, in air- and argon-satu- 
rated assay buffer, were prepared and stored at 25°C and on ice, 
respectively. Aliquots taken over a time period of 10 h were analyzed 
for the thiol content by uv measurements [14]. 
2.2. Enzyme assay 
The assay was performed at 25°C in a freshly prepared 50 mM 
borate buffer (pH 8.0) treated with dithizone to remove traces of heavy 
metals [15]; 4 mM CaCl, was added and the buffer saturated with 
argon. Stock solutions of adamalysin II were prepared as previously 
described [10,16] by centrifugation of the protein from an ammonium 
sulfate suspension and subsequent dissolution in the assay buffer. 
Enzyme concentrations were determined by uv measurements 
(e**s = 2.2. I(14 M-’ .cm-‘) and the stock solutions were stored 
in the cold. This solution was diluted 1:100 to obtain the final 
16 nM assay concentration. The fluorogenic substrate Abz-Pro-Ser- 
Phe-Leu- Tyr(NO,)-Gly-OH with a K,,, of 52 PM (MSc thesis, J.Lutz, 
Trigramin: 
Ht-e : 
Chou&Fasman: 
Garnier: 
Trigramin: 
Ht-e: 
Jararhagin: 
Rhodostamin: 
ChouhFasman: 
Garnier: 
Trigramin: 
Ht-e: 
Jararhagin: 
Rhodostamin: 
Chou&Fasman: 
Garnier: 
(1993) LMU Miinchen, in preparation) was used at a concentration 
of 21.4 PM; for the Ki determination according to Dixon [17j a 12.8 
PM concentration has also been used. Substrate fluorescence was 
measured at an excitation and emission wavelength ofn = 320 and 420 
nm, respectively, on a spectrofluorimeter (Perkin Elmer, Model 650- 
40) equipped with a thermostated cell holder. Substrate hydrolysis was 
monitored for 10 min immediately after adding the enzyme. All reac- 
tions were performed at least in triplicate. The 4 values of the inhib- 
itors were calculated from the intersection point of the straight lines 
obtained by the plots of v,,/v, vs. [I], whereas IC, values were calcu- 
lated from plots of vi/v, vs. [I) by non-linear regression with simple 
robust weighting. Errors for ICsO values were inferred from the re- 
dueed of the curve fittings. All calculations were carried out with 
the program GraFit [18]. 
3. RESULTS 
3.1. Aiignments of precursor sequences 
The known sequences of snake venom metallopro- 
teinases were all derived from the corresponding 
cDNAs. Sequence alignments of the known four 
propeptides of snake venom metalloproteinases were 
done visually. As shown in Fig. 1, this alignment re- 
quires only two single residue deletions/insertions for 
the common range. The sequence identity is between 
76% for the pair Rhodostami~ri~amin and 87% for 
Ht-efiiigramin, and the overall shared identity is still 
64%. Each propeptide sequence contains three cysteine 
residues, which are located in the homologous regions 
VEDHCYY, STASISAC and PKMCGVT, respec- 
tively. Even if the cysteines are involved in disulfide 
bridging, at least one free thiol group which could inter- 
act with the active-site zinc of the protein is therefore 
Signal-Peptide-SSI~LESGNLNDYE~PE~T --- 
Signal-Pep~ide-SSIILESG~DYEVIYPR~T --- 
HHHHHHTTT BBB 
BBBBBB BBBBBB 
~-LPKGAVQQKYEDAMQYEFKVNGEPWLHLEKNK-LFSEDYSEIHYSPDGGREITAY~SVEDHCYYHGRIENDAD --- ---- 
A-LPKGAVQPKYEDTMQYELKVrJGEPWLHLEKNKGLFSKDYSETHYSFDG-RKITTNPSVEDHCYYHGRIENDAD --- ----- 
ATRPKGAVQPKYEDAMQYEF~QEPWLH-EKNKGLFSKDYSEIHYSPDGGREITTYPPVEDHCYYHGRIENDAD --- ---- 
FFU(NYSETHYSPDGGYRITTYESVEDHCYYGGRIHDGg ---- 
HHHHHHHHHH HH - 
TT HHHHHHH~ HHHHHHHHH TTT TT TTTTTTTTT - 
STASISACDGLKGHFKLQG~YLIEPWELSDS~VFKYE~KEDEPP~CCGVT-QNWESYESTKKASQLNVTP --------__ --- _-- 
STASISACNGLKGHFKLQGEMYLIEPLKLSDSEANAVFKLDLNL ----_I----- --_--- 
STASISACNGLKGYFKLGRETYFIEPLKLPDSEAHAVFKYENVE ----c_----- --- _-- 
STASISACNGLKGHFKLGGETYFIEPMKLPDSEAMAVFKYENIEKEDESP~C~TEQNWESDEP~K~SQLNLNH ---------- --- _-- 
HHHHHH 
HHHH HHHHHHHHHHHHH 
Fig. 1. Sequence alignment and secondary structure prediction according to Chou and Fasman [11,12] and Gamier et al. (131 for the propeptides 
of Jararhagin [S], Trigramin [4], Rhodostamin [S] and Hte [2] de&teed from cDNAs. Homologies in the primary structure are underlined. Identity 
of the Chou Br Fasman and Garnier et al. prediction is underlined only if it is the same for the compared sequences. 
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present. The cysteine residue closest to the N-terminus 
of the mature protein is located in the PKMCGVT 
homologous sequence portion and therefore 21 (H&e), 
23 (Jararhagin, Trigramin) or 24 (Rhodostamin) resi- 
dues apart from the presumed starting residue of the 
mature protein sequence. This conserved cysteine se- 
quence displays homology to the peptide RCGVD, 
which has been proposed to play a role in the activation 
of the matrix metalloproteinases [9] and may therefore 
be involved in a cysteine switch-like mechanism in the 
activation of the snake venom metalloproteinases, too. 
Preferred secondary structures were predicted using 
programs based on statistical probability factors ac- 
cording to Chou and Fasman [19,20] and Garnier et al. 
[21]. Whilst the region immediately preceeding the con- 
served KPMCGV segment shows a clear preference for 
a-helix in all the propeptide segments, these programs 
predict neither a common structure for the Cys-portion 
itself nor for the subsequent sequence portion, i.e. for 
the connecting loop. Using both the sequence and con- 
fo~ational homologies of the known propeptides as 
well as the 3D structure of the catalytic domain, a model 
for the unprocessed metalloproteinases was constructed 
as shown in Fig. 2. 
Fig. 2. Model of the adamalysin If zymogen. The catalytic domain of 
the proteinase, which consists of a regulary folded ‘upper’ domain and 
a less regular ‘lower’ subdomain subdivided by the zinc-binding active 
site cleft (horizontal incision) [l], is schematically shown as an ellip- 
soid. The catalytic zinc is bound by three His residues contained in the 
zinc binding consensus equence HEXXHXXGXXH forming an ‘ac- 
tive-site helix’ and the succeeding extended strand. The X-ray struc- 
ture shows that the N-terminus of the mature proteinase starts on the 
‘left hand side’ of the molecule. In the zymogen model it is elongated 
by a propeptide which surrounds the C-terminal helix (indicated only, 
by the left hand edge of the incision), binds with the thiol function of 
a cysteine to the zinc and leaves the cleft as a helix. 
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Fig. 3. Stability of 0.8 mM KPRCGV-NH, and 2 mM reduced gluta- 
thione in 50 mM borate buffer (pH 8.0): (A) argon-saturated on ice; 
(B) air-saturated at 25°C. 
3.3. Enzyme inhibition 
As optimal assay conditions require alkaline media 
(pH 8.0), kinetic data of enzyme inhibition with cysteine 
peptides can be affected by concomitant oxidation of 
the thiol function. Correspondingly, reduced glutathi- 
one and the peptide KPRCGV-NH, were analyzed as 
model compounds for their stability in aerated assay 
buffer at 2.YC and in argon-saturated assay buffer on 
ice (Fig. 3). Practically no loss of thiol concentration 
was observed in argon-saturated buffer, whereas ca 8% 
of the thiol groups of glutathione and 60% of 
KPRCGV-NH, were oxidized in the aerated buffer over 
a period of 10 h. 
Among the peptides analyzed for their inhibitory po- 
tency, the proposed ‘cysteine switch’ peptide 
PKMCGV-NH, was found to represent he most pow- 
erful inhibitor, with an IC,, of 3.2 PM and a k; of 3.4 
PM. As shown in Fig. 4, the straight lines of the Dixon 
plot intersect in the second quadrant of the coordinate 
system supporting a predominantly competitive inhibi- 
tion mechanism. In order to assess the role of the cyste- 
ine thiol function as well as of its configuration, the 
related Ser-analog and the o-Cys diastereomer of 
PKMCGV-NH, were examined, respectively. With the 
Ser-peptide no inhibition could be observed up to a 
concentration of 1.6 mM. For the D-Cys-peptide, an 
about 20 times lower inhibition was determined in com- 
parison to the L-Cys-analog (Table I). The hexapeptide 
KPRCGV-NHZ, corresponding to the cysteine switch 
sequence of the human PMN-collagenase, was also an- 
alyzed for its inhibition of adamalysin II. It was found 
to exhibit inhibitory activity, although of significantly 
lower potency (IC,, = 67 PM) than PKMCGV-NH,, 
the cysteine peptide of the snake venom metallopro- 
teinases. On the other hand, neither cysteine nor re- 
duced glutathione, the most abundant thiol peptide in 
tissues, nor cysteine peptides with randomly selected 
sequences uch as KTFTSC or AC-WCGP-NH, were 
capable of inhibiting adamalysin II to extents compara- 
ble to PKMCGV-NH,, as evidenced by the IC,, values 
listed in Table 1. 
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Fig. 4. Dixon plot of the inhibition of adamalysin II by PKMCGV- 
NH,. 
4. DISCUSSION 
The kinetic data clearly indicate that the proposed 
cysteine switch-peptide, i.e. PKMCGV-NH,, represents 
among the peptides analyzed the most efficient inhibitor 
of the snake venom metalloproteinase adamalysin II, 
with a iui of 3.4 PM (I&, = 3.2 PM). It is about 20 times 
more potent than its D-Cys-analogue and at least 20 
times more inhibiting than the other Cys-peptides exam- 
ined. L-cysteine itself shows some inhibitory effect, but 
of much weaker intensity (ICs,, = 117 PM). Conversely, 
reduced glutathione exhibits a rather strong binding to 
the metalloproteinase. 
As PKMCGV-NH2 binds most likely to the active- 
site zinc, it can be assumed that the whole propeptide 
would exhibit a similar behaviour, although the binding 
amnities might be slightly different. Endogeneous con- 
formations stabilized by the rest of the propeptide could 
account for a more or less favourable binding, and 
therefore the question arises as to whether the affinity 
of the switch peptide is sufficiently high to protect the 
producing tissue against the collagenolytic activity, yet 
low enough to allow disruption of the thiol-zinc bond 
in the activation process of the enzyme. A too strong 
binding constant of the propeptide-derived Cys-peptide 
would prevent its release upon proteolytic cleavage at 
the connecting loop and thus, proteinase activation. On 
the other hand, in the proenzyme the Cys-peptide is 
covalently linked and correspondingly its effective con- 
centration should be su~ciently high to fully inactivate 
the enzyme, despite the moderate lui value of this pep- 
tide as separate entity. 
The number of residues separating the cysteine resi- 
due of the potential switch-peptide region from the N- 
terminus of the mature proteinase amounts to 21 (HT- 
e), 23 (Jararhagin, Trigramin) or 24 (Rhodostamin). An 
inspection of the tertiary structure of adamalysin-II, 
which is well defined from the 3rd residue onwards, 
indicates that in the hypothetical non-activated protein 
the N-terminal propeptide must bend around the C- 
terminal helix, indicated by the left edge of the incision 
in Fig. 2. This would require a chain length of at least 
30 A, corresponding to eight residues. The 21 to 24 
propeptide residues are certainly sufficient to build up 
this connective segment with a pronounced surface-ex- 
posed loop well accessible to activation proteinases. The 
propeptide would then bind into the cleft with the thiol 
group ligating the zinc atom. However, this binding 
mode would be different from that proposed for the 
substrate binding, as for the structurally related enzyme 
astacin a substrate binding from left to the right along 
the active-site edge was revealed [22,23]. 
Immediately N-terminal to the switch-peptide region, 
the secondary structure prediction (Fig. 1) suggests a 
helical stretch which presumably protrudes from the 
binding cleft. Thus the resulting zymogen model of 
adamalysin II, outlined in Fig. 2, resembles a hot dog- 
like structural motif. 
This structural model might also be valid for matrix 
metalloproteinases. Several ways of activation have 
been reported for these enzymes which may also hold 
for the snake venom metalloproteinases, i.e. activation 
by proteinases 1241, by interaction or mo~fication of the 
cysteine residue with organomer~u~als PS], metal ions 
126,271, disulfide reagents [2X], oxidants such as NaOCl 
[29] and thiol alkylating agents such as N-ethylmaleim- 
ide [27], or by conformational changes of the polypep- 
tide backbone as induced by chaotropic salts [30] and 
detergents [31]. 
Evidence exists that activation by proteinases of at 
least some of the matrixin-zymogens takes place in two 
steps 1321. The cysteine switch defines activation via the 
switch peptide with a pre-existing eq~librium between 
a zinc-bound and -unbound thiol function. This equilib- 
rium is shifted by the above mentioned activation meth- 
ods. In the zinc-unbound form the matrixins do not 
exhibit full activity which is achieved only upon autodi- 
gestion or proteolysis by other proteinases. 
In this context the results of the present study confirm 
the role of a switch-peptide in the activation of snake 
venom metalloproteinases, but cannot determine 
whether a preceeding disruption of the thiol-zinc bond 
is necessary or whether a proteolytic cleavage is suff- 
cient for activation. 
Table I 
I(?,,-values of tested compound 
Peptide &I OtM) 
PKMSGV-NH2 :, 1600 
KTFTSC 170 (k 20) 
KPRCGV-NH, 67 (?I 7) 
AC-WCGP-NH, 58 (z!z 11) 
PKM(L-)CGV-NH, 3.2’ (+0.6) 
PKM(D-)CGV-NH, 74 (k 6) 
L-Cysteine 117# (2 11) 
Red. glutathione 50” (rf: 8) 
The # indicates the average of two m~surements at different substrate 
concent~tions 
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As described previously [33], the superfamily of 
metalloproteinases with the consensus sequence 
HEXXHXXGXXH, which have been called Metzincins 
due to a conserved methionine turn that forms a hydro- 
phobic basis for the zinc ion and the three liganding 
histidine residues, can be divided into the families of the 
matrix metalloproteinases (‘matrixins’), the snake 
venom metalloproteinases (‘adamalysins’), the serratia 
proteases (‘serralysins’) and the members of the astacin 
family (‘astacins’). No cysteine or cysteine switch pep- 
tide sequence have been found in the propeptide of the 
serralysin of Erwinia chrysantemi [34] or in the propep- 
tide sequence of astacin (W. Stocker, personal commu- 
nication). Members of these families are probably acti- 
vated by a different mechanism. In fact, a tyrosine is 
found as additional fifth zinc ligand in these two fami- 
lies [35,1] which is absent in the two other families. The 
presence of a tyrosine correlates well with the absence 
of the cysteine-switch region because of possible sterical 
interferences of the tyrosine residue with a cysteine sup- 
plied by a potential propeptide. 
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